Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia absinthium pollen extract is a biological product derived from the pollen of the wormwood plant, used primarily in the field of allergology. It serves a dual purpose: as a diagnostic tool for identifying type I hypersensitivity through skin prick testing and as a therapeutic agent in allergen immunotherapy (AIT). The extract contains a complex mixture of proteins (allergens) that, when introduced to a sensitized individual, cross-link IgE antibodies bound to the high-affinity IgE receptor (FcεRI) on mast cells and basophils, triggering the release of inflammatory mediators. In the context of immunotherapy, repeated exposure to increasing doses of the extract aims to induce immunological tolerance, characterized by a shift from a Th2-dominated allergic response to a Th1/Treg response and the production of blocking IgG4 antibodies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia absinthium pollen extract.